152 related articles for article (PubMed ID: 37708796)
1. The latest perspectives of small molecules FMS kinase inhibitors.
Alkubaisi BO; Aljobowry R; Ali SM; Sultan S; Zaraei SO; Ravi A; Al-Tel TH; El-Gamal MI
Eur J Med Chem; 2023 Dec; 261():115796. PubMed ID: 37708796
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in colony stimulating factor-1 receptor/c-FMS as an emerging target for various therapeutic implications.
Kumari A; Silakari O; Singh RK
Biomed Pharmacother; 2018 Jul; 103():662-679. PubMed ID: 29679908
[TBL] [Abstract][Full Text] [Related]
3. FMS Kinase Inhibitors: Current Status and Future Prospects.
El-Gamal MI; Anbar HS; Yoo KH; Oh CH
Med Res Rev; 2013 May; 33(3):599-636. PubMed ID: 22434539
[TBL] [Abstract][Full Text] [Related]
4. Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
Farag AK; Elkamhawy A; Londhe AM; Lee KT; Pae AN; Roh EJ
Eur J Med Chem; 2017 Dec; 141():657-675. PubMed ID: 29107425
[TBL] [Abstract][Full Text] [Related]
5. Recent Advances of Colony-Stimulating Factor-1 Receptor (CSF-1R) Kinase and Its Inhibitors.
El-Gamal MI; Al-Ameen SK; Al-Koumi DM; Hamad MG; Jalal NA; Oh CH
J Med Chem; 2018 Jul; 61(13):5450-5466. PubMed ID: 29293000
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic intervention in leukemias that express the activated fms-like tyrosine kinase 3 (FLT3): opportunities and challenges.
Sternberg DW; Licht JD
Curr Opin Hematol; 2005 Jan; 12(1):7-13. PubMed ID: 15604885
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and structure-activity relationship of diaryl-ureas with novel isoxazol[3,4-b]pyridine-3-amino-structure as multi-target inhibitors against receptor tyrosine kinase.
Shi ZH; Liu FT; Tian HZ; Zhang YM; Li NG; Lu T
Bioorg Med Chem; 2018 Sep; 26(16):4735-4744. PubMed ID: 30121211
[TBL] [Abstract][Full Text] [Related]
8. Role of Tyrosine Kinases and their Inhibitors in Cancer Therapy: A Comprehensive Review.
Kumar V; Kaur N; Sahu S; Sharma V; Kumar D; Sharma A; Wadhwa P
Curr Med Chem; 2023; 30(13):1464-1481. PubMed ID: 35894454
[TBL] [Abstract][Full Text] [Related]
9. Recent advances of pyrrolopyridines derivatives: a patent and literature review.
El-Gamal MI; Anbar HS
Expert Opin Ther Pat; 2017 May; 27(5):591-606. PubMed ID: 28064544
[TBL] [Abstract][Full Text] [Related]
10. Discovery of a new potent bisamide FMS kinase inhibitor.
El-Gamal MI; Jung MH; Oh CH
Bioorg Med Chem Lett; 2010 Jun; 20(11):3216-8. PubMed ID: 20457522
[TBL] [Abstract][Full Text] [Related]
11. A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model.
Ohno H; Kubo K; Murooka H; Kobayashi Y; Nishitoba T; Shibuya M; Yoneda T; Isoe T
Mol Cancer Ther; 2006 Nov; 5(11):2634-43. PubMed ID: 17121910
[TBL] [Abstract][Full Text] [Related]
12. Pyrrolo[3,2-c]pyridine derivatives with potential inhibitory effect against FMS kinase: in vitro biological studies.
El-Gamal MI; Oh CH
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):1160-1166. PubMed ID: 30070930
[TBL] [Abstract][Full Text] [Related]
13. Small molecule inhibitors of the class 1 receptor tyrosine kinase family.
Cockerill GS; Lackey KE
Curr Top Med Chem; 2002 Sep; 2(9):1001-10. PubMed ID: 12171567
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and evaluation of thieno[3,2-d]pyrimidine derivatives as novel FMS inhibitors.
Kim YY; Choi J; Choi K; Park C; Kim YH; Suh KH; Ham YJ; Jang SY; Lee KH; Hwang KW
Bioorg Med Chem Lett; 2019 Jan; 29(2):271-275. PubMed ID: 30522957
[TBL] [Abstract][Full Text] [Related]
15. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
16. Discoidin domain receptor inhibitors as anticancer agents: A systematic review on recent development of DDRs inhibitors, their resistance and structure activity relationship.
Shenoy GP; Pal R; Purwarga Matada GS; Singh E; Raghavendra NM; Dhiwar PS
Bioorg Chem; 2023 Jan; 130():106215. PubMed ID: 36384067
[TBL] [Abstract][Full Text] [Related]
17. JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia.
Manthey CL; Johnson DL; Illig CR; Tuman RW; Zhou Z; Baker JF; Chaikin MA; Donatelli RR; Franks CF; Zeng L; Crysler C; Chen Y; Yurkow EJ; Boczon L; Meegalla SK; Wilson KJ; Wall MJ; Chen J; Ballentine SK; Ott H; Baumann C; Lawrence D; Tomczuk BE; Molloy CJ
Mol Cancer Ther; 2009 Nov; 8(11):3151-61. PubMed ID: 19887542
[TBL] [Abstract][Full Text] [Related]
18. Recent Development in the Discovery of Anaplastic Lymphoma Kinase (ALK) Inhibitors for Non-small Cell Lung Cancer.
Liu J; Ma S
Curr Med Chem; 2017; 24(6):590-613. PubMed ID: 27804873
[TBL] [Abstract][Full Text] [Related]
19. Substrate specificities and identification of a putative binding site for PI3K in the carboxy tail of the murine Flt3 receptor tyrosine kinase.
Rottapel R; Turck CW; Casteran N; Liu X; Birnbaum D; Pawson T; Dubreuil P
Oncogene; 1994 Jun; 9(6):1755-65. PubMed ID: 8183574
[TBL] [Abstract][Full Text] [Related]
20. FDA-approved small-molecule kinase inhibitors.
Wu P; Nielsen TE; Clausen MH
Trends Pharmacol Sci; 2015 Jul; 36(7):422-39. PubMed ID: 25975227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
